Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Sayers Website

Thomas J. Sayers, Ph.D.

Selected Publications
1)  Mathews LA, Keller JM, Goodwin BL, Guha R, Shinn P, Mull R, Thomas CJ, de Kluyver RL, Sayers TJ, Ferrer M.
A 1536-well quantitative high-throughput screen to identify compounds targeting cancer stem cells.
J Biomol Screen. 17: 1231-42, 2012. [Journal]
2)  Henrich CJ, Thomas CL, Brooks AD, Booth NL, Lowery EM, Pompei RJ, McMahon JB, Sayers TJ.
Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis.
Apoptosis. 17: 79-89, 2012. [Journal]
3)  Whitson EL, Sun H, Thomas CL, Henrich CJ, Sayers TJ, McMahon JB, Griesinger C, McKee TC.
Synergistic TRAIL sensitizers from Barleria alluaudii and Diospyros maritima.
J. Nat. Prod. 75: 394-9, 2012. [Journal]
4)  Sayers TJ.
Targeting the extrinsic apoptosis signaling pathway for cancer therapy.
Cancer Immunol. Immunother. 60: 1173-80, 2011. [Journal]
5)  Seki N, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, Kusukawa J, Kage M, Shirouzu K, Yamana H.
Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
Mol. Cancer Ther. 9: 1842-51, 2010. [Journal]
6)  Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ.
Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Mol. Cancer Res. 8: 729-38, 2010. [Journal]
7)  de Kluyver RL, Sayers TJ.
Breast cancer bone metastases: Combination therapy targeting cancer cells and the tumor microenvironment.
Cancer Biol Ther. 9: 551-3, 2010. [Journal]
8)  Zaritskaya L, Shurin MR, Sayers TJ, Malyguine AM.
New flow cytometric assays for monitoring cell-mediated cytotoxicity.
Expert Rev Vaccines. 9: 601-16, 2010. [Journal]
9)  Lee S, Yagita H, Sayers TJ, Celis E.
Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.
Cancer Immunol. Immunother. 59: 1073-81, 2010. [Journal]
10)  Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, Tan S, Kaiser J, Shanmugavelandy SS, Rogers A, Loughran K, Petersen B, Yuen J, Meng F, Baab KT, Jarbadan NR, Broeg K, Zhang R, Liao J, Sayers TJ, Kester M, Loughran TP.
Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia.
Blood. 116: 4192-201, 2010. [Journal]
11)  Shanker A, Brooks AD, Jacobsen KM, Wine JW, Wiltrout RH, Yagita H, Sayers TJ.
Antigen Presented by Tumors In vivo Determines the Nature of CD8+ T-Cell Cytotoxicity.
Cancer Res. 69: 6615-23, 2009. [Journal]
12)  Salcedo R, Hixon JA, Stauffer JK, Jalah R, Brooks AD, Khan T, Dai RM, Scheetz L, Lincoln E, Back TC, Powell D, Hurwitz AA, Sayers TJ, Kastelein R, Pavlakis GN, Felber BK, Trinchieri G, Wigginton JM.
Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.
J. Immunol. 182: 4328-38, 2009. [Journal]
13)  Booth NL, Sayers TJ, Brooks AD, Thomas CL, Jacobsen K, Goncharova EI, McMahon JB, Henrich CJ.
A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.
Cancer Immunol. Immunother. 58: 1229-44, 2008. [Journal]
14)  Sayers T.
Productively combining proteasome inhibition with the immunotherapy of cancer.
J. Mol. Med. 86: 857-60, 2008. [Journal]
15)  Sun K, Li M, Sayers TJ, Welniak LA, Murphy WJ.
Differential effects of donor T cell cytokines on outcome with continuous bortezomib administration following allogeneic bone marrow transplantation.
Blood. 112: 1522-9, 2008. [Journal]
16)  Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ.
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
J. Natl. Cancer Inst. 100: 649-62, 2008. [Journal]
17)  Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, Sayers TJ, Hudig D, Murphy WJ.
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
J. Immunol. 180: 163-70, 2008. [Journal]
18)  Khan T, Stauffer JK, Williams R, Hixon JA, Salcedo R, Lincoln E, Back TC, Powell D, Lockett S, Arnold AC, Sayers TJ, Wigginton JM.
Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.
J. Immunol. 176: 6302-12, 2006. [Journal]
19)  Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ.
TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.
Immunol. Cell Biol. 84: 87-98, 2006. [Journal]
20)  Abdool K, Cretney E, Brooks AD, Kelly JM, Swann J, Shanker A, Bere EW, Yokoyama WM, Ortaldo JR, Smyth MJ, Sayers TJ.
NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function.
J. Immunol. 177: 2575-83, 2006. [Journal]
21)  Lee JK, Seki N, Sayers TJ, Subleski J, Gruys EM, Murphy WJ, Wiltrout RH.
Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L.
Cell. Immunol. 235: 145-52, 2005. [Journal]
22)  Sun K, Wilkins DE, Anver MR, Sayers TJ, Panoskaltsis-Mortari A, Blazar BR, Welniak LA, Murphy WJ.
Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.
Blood. 106: 3293-9, 2005. [Journal]
23)  Brooks AD, Ramirez T, Toh U, Onksen J, Elliott PJ, Murphy WJ, Sayers TJ.
The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.
Ann. N. Y. Acad. Sci. 1059: 160-7, 2005. [Journal]
24)  Sayers TJ, Murphy WJ.
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Cancer Immunol Immunother. 55: 76-84, 2005. [Journal]
25)  Brooks AD, Sayers TJ.
Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis.
Cancer Immunol Immunother. 54: 499-505, 2005. [Journal]
26)  Shafer-Weaver KA, Sayers T, Kuhns DB, Strobl SL, Burkett MW, Baseler M, Malyguine A.
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay.
J Transl Med. 2: 31, 2004. [Journal]
27)  Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I, Riordan W, Sitcheran R, Wysocki C, Serody JS, Blazar BR, Sayers TJ, Murphy WJ.
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
Proc Natl Acad Sci U S A. 101: 8120-5, 2004. [Journal]
28)  Sayers TJ.
TNF-related apoptosis inducing ligand (TRAIL): Combination with proteasome inhibition for anticancer therapy.
Proteasome Inhibition in Cancer Therapy. Ed. J Adams,. Humana Press, Totowa, NJ: 181-191, 2004. [Journal]
29)  Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H, Smyth MJ.
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.
J Exp Med. 199: 437-48, 2004. [Journal]
30)  Sedelies KA, Sayers TJ, Edwards KM, Chen W, Pellicci DG, Godfrey DI, Trapani JA.
Discordant regulation of granzyme H and granzyme B expression in human lymphocytes.
J Biol Chem. 279: 26581-7, 2004. [Journal]
31)  Smyth MJ, Swann J, Kelly JM, Cretney E, Yokoyama WM, Diefenbach A, Sayers TJ, Hayakawa Y.
NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.
J Exp Med. 200: 1325-35, 2004. [Journal]
32)  Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, Seki N, Wigginton JM, Wilson SE, Blazar BR, Malyguine AM, Sayers TJ, Wiltrout RH.
Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.
J Immunol. 170: 2727-33, 2003. [Journal]
33)  Komatsu M, Mammolenti M, Jones M, Jurecic R, Sayers TJ, Levy RB.
Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing.
Blood. 101: 3991-9, 2003. [Journal]
34)  Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ.
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.
Blood. 102: 303-10, 2003. [Journal]
35)  Shafer-Weaver K, Sayers T, Strobl S, Derby E, Ulderich T, Baseler M, Malyguine A.
The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity.
J Transl Med. 1: 14, 2003. [Journal]
36)  Lee JK, Sayers TJ, Back TC, Wigginton JM, Wiltrout RH.
Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer.
Apoptosis. 8: 151-60, 2003. [Journal]
37)  Sayers TJ.
Granzyme M, a profile of innate immune lymphocytes.
Blood. 101: 3342b-3343b, 2003. [Journal]
38)  Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, Tanner JE, Smyth MJ, Sayers TJ.
Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.
Cancer Res. 63: 207-13, 2003. [Journal]
39)  Malyguine A, Derby E, Brooks A, Reddy V, Baseler M, Sayers T.
Study of diverse mechanisms of cell-mediated cytotoxicity in gene-targeted mice using flow cytometric cytotoxicity assay.
Immunol Lett. 83: 55-9, 2002. [Journal]
40)  Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.
Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
J Immunol. 168: 3484-92, 2002. [Journal]
41)  Derby E, Reddy V, Kopp W, Nelson E, Baseler M, Sayers T, Malyguine A.
Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity.
Immunol Lett. 78: 35-9, 2001. [Journal]
42)  Smyth MJ, Kelly JM, Sutton VR, Davis JE, Browne KA, Sayers TJ, Trapani JA.
Unlocking the secrets of cytotoxic granule proteins.
J Leukoc Biol. 70: 18-29, 2001. [Journal]
43)  Sayers TJ, Brooks AD, Ward JM, Hoshino T, Bere WE, Wiegand GW, Kelly JM, Smyth MJ, Kelley JM.
The restricted expression of granzyme M in human lymphocytes.
J Immunol. 166: 765-71, 2001. [Journal]
44)  Sayers TJ, Brooks AD, Seki N, Smyth MJ, Yagita H, Blazar BR, Malyguine AM.
T cell lysis of murine renal cancer: multiple signaling pathways for cell death via Fas.
J Leukoc Biol. 68: 81-6, 2000. [Journal]
45)  Lee JK, Sayers TJ, Brooks AD, Back TC, Young HA, Komschlies KL, Wigginton JM, Wiltrout RH.
IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells.
J Immunol. 164: 231-9, 2000. [Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 4/29/2013.